Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer

Published:2024-06 Issue:6 Volume:30 Page:581-587
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Suh Kangho¹,Kang Ashley²,Ko Gilbert³,Williamson Todd³,Liao Nick³,Sullivan Sean D.⁴

Affiliation:

1. Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, PA.

2. Curta Inc., Seattle, WA.

3. Bayer U.S. LLC, Whippany, NJ.

4. Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle.

Publisher

Academy of Managed Care Pharmacy

Reference21 articles.

1. Targeted therapies for cancer

2. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

3. Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021

4. Efficacy of Larotrectinib inTRKFusion–Positive Cancers in Adults and Children

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP